1. Janssen Pharmaceutical, and Bayer Yakuhin, outside of the submitted work. Ikeda N reports personal fees from Janssen Pharmaceutical, Bayer Yakuhin, Nippon Shinyaku, Daiichi Sankyo, and Bristol-Myers Squibb, outside of the submitted work. Shimokawahara H reports a grant from Bayer Yakuhin; personal fees from Actelion Pharmaceuticals Japan, Bayer Yakuhin, and Nippon Shinyaku, outside of the submitted work;Kawakami T reports personal fees from Kaneka Medix, Abbott Medical Japan., and Acist Japan, outside of the submitted work. Hatano M reports personal fees from Janssen Pharmaceutical and Bayer Yakuhin, outside of the submitted work. Ogino H reports grants from Daiichi Sankyo, Nippon Boehringer Ingelheim, Pfizer Japan, Eisai, GlaxoSmithKline, Mochida Pharmaceutical, Janssen Pharmaceutical, and Nippon Shinyaku; consulting fees from Terumo, Japan Lifeline, and Century Medical; personal fees from Bayer Yakuhin, Daiichi Sankyo, Pfizer Japan, and Nippon Shinyaku, outside of the submitted work
2. Kaneka Medix, and Janssen Pharmaceutical; membership on board of directors or advisory committees for International CTEPH Association and Japanese Pulmonary Circulation and Pulmonary Hypertension Society, outside of the submitted work; and he is on the data safety monitoring boards for Janssen Pharmaceutical, United Therapeutics, and Bayer, outside of the submitted work. Fukuda K reports grants from Bayer Yakuhin, Daiichi Sankyo, Nippon Boehringer Ingelheim, Pfizer, Eisai, Janssen Pharmaceutical, Nippon Shinyaku, GlaxoSmithKline, and Mochida Pharmaceutical; personal fees from Bayer Yakuhin, Daiichi Sankyo;Bayer Pharmaceutical;Nippon Boehringer Ingelheim, Pfizer., Eisai, Janssen Pharmaceutical, Nippon Shinyaku, GlaxoSmithKline, and Mochida Pharmaceutical, outside of the submitted work. Tsutsui H reports grants from Mitsubishi Tanabe Pharma, IQVIA Services Japan, MEDINET, Medical Innovation Kyushu
3. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature;Y M Ende-Verhaar;Eur Respir J,2017
4. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA;H Gall;Europe and Japan,2017
5. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry;M Delcroix;Circulation,2016